RT Journal Article
SR Electronic
A1 Vinall, Phil
T1 Effects of 12 Weeks of Treatment with RN316 (PF-04950615) in Hypercholesterolemic Subjects on High and Maximal Dose Statins
JF MD Conference Express
YR 2012
FD SAGE Publications
VO 12
IS 18
SP 19
OP 20
DO 10.1177/155989771218010
UL http://mdc.sagepub.com/content/12/18/19.abstract
AB Results from two Phase 2 trials indicate that intravenous infusions of RN316, a humanized IgG2?a monoclonal antibody that inhibits proprotein convertase subtilisin kexin type 9 (PCSK9), significantly lowers low-density lipoprotein cholesterol in hypercholesterolemic subjects already on high to maximal doses of statins.